Cargando…

Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor

The emergence of acquired resistance is a major concern associated with molecularly targeted kinase inhibitors. The C797S mutation in the epidermal growth factor receptor (EGFR) confers resistance to osimertinib, a third‐generation EGFR‐tyrosine kinase inhibitor (EGFR‐TKI). We report that the deriva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishiya, Naoyuki, Oku, Yusuke, Ishikawa, Chie, Fukuda, Tsutomu, Dan, Shingo, Mashima, Tetsuo, Ushijima, Masaru, Furukawa, Yoko, Sasaki, Yuka, Otsu, Keishi, Sakyo, Tomoko, Abe, Masanori, Yonezawa, Honami, Ishibashi, Fumito, Matsuura, Masaaki, Tomida, Akihiro, Seimiya, Hiroyuki, Yamori, Takao, Iwao, Masatomo, Uehara, Yoshimasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088975/ https://www.ncbi.nlm.nih.gov/pubmed/33544933 http://dx.doi.org/10.1111/cas.14839

Ejemplares similares

Anticancer Alkaloid Lamellarins Inhibit Protein Kinases
por: Baunbæk, Dianne, et al.
Publicado: (2008)

Synthesis of lamellarin R, lukianol A, lamellarin O and their analogues
por: Satyanarayana, Iddum, et al.
Publicado: (2020)

Anticancer Properties of Lamellarins
por: Bailly, Christian
Publicado: (2015)

Structural insights into drug development strategy targeting EGFR T790M/C797S
por: Zhu, Su-Jie, et al.
Publicado: (2018)

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors
por: Jia, Yong, et al.
Publicado: (2016)

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
por: Lategahn, Jonas, et al.
Publicado: (2019)

Synthetic Approaches to the Lamellarins—A Comprehensive Review
por: Imbri, Dennis, et al.
Publicado: (2014)

Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation
por: Mashima, Tetsuo, et al.
Publicado: (2015)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
por: Wang, Shuhang, et al.
Publicado: (2016)

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
por: Zhou, Rengui, et al.
Publicado: (2021)

Synthesis of lamellarin alkaloids using orthoester-masked α-keto acids
por: Shirley, Harry J., et al.
Publicado: (2019)

Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M
por: Thress, Kenneth S., et al.
Publicado: (2015)

Gastric manometric abnormalities in patients with dyspeptic symptoms after fundoplication: V. Stanghellini and J. R. Malagelada. Gut 24:790–797, (September), 1983
por: Puri, P.
Publicado: (1984)

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
por: Enrico, Diego, et al.
Publicado: (2022)

Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
por: Wang, Yanyan, et al.
Publicado: (2023)

Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review
por: Fang, Yue, et al.
Publicado: (2023)

Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
por: Nishiya, Naoyuki, et al.
Publicado: (2019)

Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers
por: Oku, Yusuke, et al.
Publicado: (2015)

Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP–E2F1–DNA damage response pathway axis
por: Oku, Yusuke, et al.
Publicado: (2018)

Pyrazole-based lamellarin O analogues: synthesis, biological evaluation and structure–activity relationships
por: Dzedulionytė, Karolina, et al.
Publicado: (2023)

EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR
por: Madic, Jordan, et al.
Publicado: (2018)

Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer
por: Akazawa, Yu, et al.
Publicado: (2020)

AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
por: Choi, Geunho, et al.
Publicado: (2021)

Early-Onset Pulmonary Events with Combined Brigatinib and Afatinib Treatment of L858/ cisT790M/cisC797S NSCLC: A Case Report
por: Lee, Bing-Jie, et al.
Publicado: (2022)

Novel 5, 6-Dihydropyrrolo[2,1-a]isoquinolines as Scaffolds for Synthesis of Lamellarin Analogues
por: Liao, Shao Han, et al.
Publicado: (2011)

Correction: EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR
por: Madic, Jordan, et al.
Publicado: (2019)

Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
por: Suriya, Utid, et al.
Publicado: (2022)

Multimodal Effects of Small Molecule ROCK and LIMK Inhibitors on Mitosis, and Their Implication as Anti-Leukemia Agents
por: Oku, Yusuke, et al.
Publicado: (2014)

In silico design of EGFR(L858R/T790M/C797S) inhibitors via 3D-QSAR, molecular docking, ADMET properties and molecular dynamics simulations
por: Hadni, Hanine, et al.
Publicado: (2022)

Ivermectin represses Wnt/β-catenin signaling by binding to TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases
por: Yonezawa, Honami, et al.
Publicado: (2022)

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients
por: Yang, Yaning, et al.
Publicado: (2021)

Feiyiliu Mixture sensitizes EGFR(Del19/T790M/C797S) mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway
por: Shi, Jingjing, et al.
Publicado: (2023)

Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report
por: Zhao, Jing, et al.
Publicado: (2018)

Homobivalent Lamellarin-Like Schiff Bases: In Vitro Evaluation of Their Cancer Cell Cytotoxicity and Multitargeting Anti-Alzheimer’s Disease Potential
por: Nevskaya, Alisa A., et al.
Publicado: (2021)

De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy
por: Mashima, T, et al.
Publicado: (2009)

Edition Eulenburg No. 797, Horn Concerto, : Mi♭ majeur - E♭ major - Es dur KV 495 /

797. Tuberculosis Treatment: Combined Forms vs. Dissociated Forms
por: Trigui, Maroua, et al.
Publicado: (2018)

Another Facet to the Anticancer Response to Lamellarin D: Induction of Cellular Senescence through Inhibition of Topoisomerase I and Intracellular Ros Production
por: Ballot, Caroline, et al.
Publicado: (2014)

Molecular docking study of lamellarin analogues and identification of potential inhibitors of HIV-1 integrase strand transfer complex by virtual screening
por: Eurtivong, Chatchakorn, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_83334a23q4o2qovu5p1hlefkjd